BioSpace

Lilly’s retatrutide trounces Novo’s Ozempic in diabetes, weight loss

Eli Lilly’s next-gen weight loss drug retatrutide soundly beat Novo’s approved medicine Ozempic in weight loss and blood sugar reduction, padding the case for a regulatory application that’s expected in the first quarter of 2027.

By BioSpace

1 min read
Lilly’s retatrutide trounces Novo’s Ozempic in diabetes, weight loss
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights